Nucleic acids encoding polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
1. A nucleic acid comprising a nucleotide sequence that encodes a polypeptide that comprises at least one immunoglobulin single variable domain (ISVD) that specifically binds to IL-13 or TSLP, wherein said ISVD comprises three complementarity determining regions (CDR1 to CDR3, respectively); and wherein the at least one ISVD comprises:
a) a CDR1 that comprises the amino acid sequence of SEQ ID NO: 7;
a CDR2 that comprises the amino acid sequence of SEQ ID NO: 12; and
a CDR3 that comprises the amino acid sequence of SEQ ID NO: 17,
b) a CDR1 that comprises the amino acid sequence of SEQ ID NO: 8;
a CDR2 that comprises the amino acid sequence of SEQ ID NO: 13; and
a CDR3 that comprises the amino acid sequence of SEQ ID NO: 18,
c) a CDR1 that comprises the amino acid sequence of SEQ ID NO: 9;
a CDR2 that comprises the amino acid sequence of SEQ ID NO: 14; and
a CDR3 that comprises the amino acid sequence of SEQ ID NO: 19; or
d) a CDR1 that comprises the amino acid sequence of SEQ ID NO: 11;
a CDR2 that comprises the amino acid sequence of SEQ ID NO: 16; and
a CDR3 that comprises the amino acid sequence of SEQ ID NO: 21.
2. The nucleic acid according to claim 1 , wherein said at least one ISVD that specifically binds to IL-13 or TSLP comprises:
a) the amino acid sequence of SEQ ID NO: 2,
b) the amino acid sequence of SEQ ID NO: 3,
c) the amino acid sequence of SEQ ID NO: 4, or
d) the amino acid sequence of SEQ ID NO: 6.
3. The nucleic acid according to claim 1 , wherein the polypeptide comprises at least two ISVDs, wherein each of said ISVDs comprises three complementarity determining regions (CDR1 to CDR3, respectively), wherein the at least two ISVDs are optionally linked via one or more peptidic linkers, and wherein:
a) a first and a second ISVD specifically bind to IL-13, each comprising
i. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 7;
ii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 12; and
iii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 17,
b) a first and a second ISVD specifically bind to IL-13, each comprising
i. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 8;
ii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 13; and
iii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 18,
c) a first ISVD specifically binds to IL-13 and comprises
i. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 7;
ii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 12; and
iii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 17, and
a second ISVD specifically binds to IL-13 and comprises
iv. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 8;
v. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 13; and
vi. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 18,
d) a first ISVD specifically binds to IL-13 and comprises
i. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 8;
ii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 13; and
iii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 18, and
a second ISVD specifically binds to IL-13 and comprises
iv. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 7;
v. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 12; and
vi. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 17,
e) a first ISVD specifically binds to TSLP and comprises
i. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 11;
ii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 16; and
iii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 21, and
a second ISVD specifically binds to TSLP and comprises
iv. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 9;
v. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 14; and
vi. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 19, or
f) a first ISVD specifically binds to TSLP and comprises
i. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 9;
ii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 14; and
iii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 19, and
a second ISVD specifically binds to TSLP and comprises
iv. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 11;
v. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 16; and
vi. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 21,
wherein the order of the ISVDs indicates their relative position to each other considered from the N-terminus to the C-terminus of said polypeptide.
4. The nucleic acid according to claim 3 , wherein the polypeptide comprises:
a) the amino acid sequence of SEQ ID NO: 148,
b) the amino acid sequence of SEQ ID NO: 149,
c) the amino acid sequence of SEQ ID NO: 150,
d) the amino acid sequence of SEQ ID NO: 151,
e) the amino acid sequence of SEQ ID NO: 152,
f) the amino acid sequence of SEQ ID NO: 153,
g) the amino acid sequence of SEQ ID NO: 154,
h) the amino acid sequence of SEQ ID NO: 155,
i) the amino acid sequence of SEQ ID NO: 156,
j) the amino acid sequence of SEQ ID NO: 157,
k) the amino acid sequence of SEQ ID NO: 158, or
l) the amino acid sequence of SEQ ID NO: 159.
5. The nucleic acid according to claim 1 , wherein the polypeptide comprises at least four ISVDs, wherein each of said ISVDs comprises three complementarity determining regions (CDR1 to CDR3, respectively), wherein the at least four ISVDs are optionally linked via one or more peptidic linkers, and wherein:
a) a first ISVD specifically binds to IL-13 and comprises
i. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 7;
ii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 12; and
iii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 17,
b) a second ISVD specifically binds to IL-13 and comprises
iv. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 8;
v. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 13; and
vi. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 18,
c) a third ISVD specifically binds to TSLP and comprises
vii. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 9;
viii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 14; and
ix. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 19, and
d) a fourth ISVD specifically binds to TSLP and comprises
x. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 11;
xi. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 16; and
xii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 21,
wherein the order of the ISVDs indicates their relative position to each other considered from the N-terminus to the C-terminus of said polypeptide.
6. The nucleic acid according to claim 5 , wherein:
a) said first ISVD comprises the amino acid sequence of SEQ ID NO: 2;
b) said second ISVD comprises the amino acid sequence of SEQ ID NO: 3;
c) said third ISVD comprises the amino acid sequence of SEQ ID NO: 4; and
d) said fourth ISVD comprises the amino acid sequence of SEQ ID NO: 6.
7. The nucleic acid according to claim 5 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1.
8. The nucleic acid according to claim 7 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1.
9. The nucleic acid according to claim 1 , wherein said polypeptide further comprises one or more other groups, residues, moieties or binding units, optionally linked via one or more peptidic linkers, in which said one or more other groups, residues, moieties or binding units provide the polypeptide with increased half-life, compared to the corresponding polypeptide without said one or more other groups, residues, moieties or binding units.
10. The nucleic acid according to claim 9 , in which said one or more other groups, residues, moieties or binding units that provide the polypeptide with increased half-life is selected from the group consisting of binding units that binds to serum albumin and a serum immunoglobulin.
11. The nucleic acid according to claim 10 , wherein the serum albumin is human serum albumin, and the serum immunoglobulin is an IgG.
12. The nucleic acid according to claim 10 , in which said binding unit that provides the polypeptide with increased half-life is an ISVD that binds to human serum albumin.
13. The nucleic acid according to claim 12 , wherein the ISVD binding to human serum albumin comprises a CDR1 that comprises the amino acid sequence of SEQ ID NO: 10, a CDR2 that comprises the amino acid sequence of SEQ ID NO: 15 and a CDR3 that comprises the amino acid sequence of SEQ ID NO: 20.
14. The nucleic acid according to claim 12 , wherein said ISVD binding to human serum albumin comprises the amino acid sequence of SEQ ID NO: 5.
15. An isolated host cell comprising the nucleic acid according to claim 1 .
16. A method for producing a polypeptide encoded by the nucleic acid of claim 1 comprising:
a) expressing the nucleic acid in an isolated host cell under suitable conditions for producing the polypeptide; optionally followed by:
b) isolating and/or purifying the polypeptide.